Neoadjuvant Docetaxel-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreas

Olivier Turrini (1) , Marc Ychou (2) , Laurence Moureau-Zabotto (3) , Philippe Rouanet (4) , Marc Giovannini (5) , Vincent Moutardier (1) , David Azria (6) , Jean-Robert Delpero (1) , Frédéric Viret (7)

1 Department of Surgical Oncology
2 Department of Medical Oncology
3 Département de Radiothérapie
4 Department of Surgical Oncology
5 Department of Endoscopy
6 Department of Radiotherapy
7 Department of Medical Oncology

To assess the safety and efficacy of a new neoadjuvant chemoradiation (CRT) docetaxel-based regimen in patients with resectable adenocarcinoma of the pancreatic head or body.

Mots clés: Medicine

Olivier Turrini, Marc Ychou, Laurence Moureau-Zabotto, Philippe Rouanet, Marc Giovannini, et al.. Neoadjuvant Docetaxel-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreas. EJSO - European Journal of Surgical Oncology, 2010, 36 (10), pp.987. ⟨10.1016/j.ejso.2010.07.003⟩. ⟨hal-00625561⟩